Our initial findings suggest that disruption of FABP4 activity can reduce viability and enhance drug sensitivity in these organoids, indicating the potential of FABP4 inhibitors as adjuncts to current EGFR-targeted therapies for overcoming drug resistance in CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.